DIAMEDICA THERAPEUT.

DiaMedica reported an adjusted loss of $0.19 per share in the second quarter, exactly matching consensus, and no revenue. The biotech company observed significant blood pressure effects in the late preeclampsia study, completed the first cohort in the early fetal growth restriction trial, and has recruited over 85% of patients for the ReMEDy2 stroke interim analysis. Cash and equivalents amounted to $43.5 million as of June 30, which management says should fund operations and studies through 2027, while R&D expenses rose markedly. The stock reacted positively in premarket trading; near‑term milestones include further cohort recruitment, top‑line data and steps toward a U.S. IND submission. » Mere på de.investing.com

1 Main Capital said it holds an opportunistic position in DiaMedica Therapeutics, citing DM199, a recombinant form of tissue kallikrein‑1 (KLK1), as a promising therapy for ischemic stroke recovery. The fund noted extensive real‑world use of naturally derived KLK1 in China and positive signals from pooled and Phase 4 studies, while acknowledging those data are not FDA‑caliber and DM199 is not identical to the Chinese product. DiaMedica closed at $6.34 on July 31, 2026, with a market cap near $342 million and mixed recent returns. » Mere på finance.yahoo.com

DiaMedica Therapeutics reported Q4 2025 EPS of -$0.17, slightly above expectations, and increased cash and equivalents to $59.9 million (+35.8%). Operating cash outflow rose due to higher R&D spending, including the expansion of the ReMEDy2 study. Management expects current liquidity to fund operations through the end of 2027; the stock fell 2.21% in after-hours trading. » Mere på de.investing.com